The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ET190L1-ARTEMIS T cell therapy to induce complete remission of relapsed and refractory (r/r) B-cell lymphoma with no cytokine release syndrome in the first-in-human clinical study.
 
Zhi Tao Ying
No Relationships to Disclose
 
Li Long
Employment - Eureka Therapeutics
Leadership - Eureka Therapeutics
Stock and Other Ownership Interests - Eureka Therapeutics
Honoraria - Eureka Therapeutics
Travel, Accommodations, Expenses - Eureka Therapeutics
 
Hong Liu
Employment - Eureka Therapeutics
Leadership - Eureka Therapeutics
Stock and Other Ownership Interests - Eureka Therapeutics
Honoraria - Eureka Therapeutics
Travel, Accommodations, Expenses - Eureka Therapeutics
 
Mei Zhang
No Relationships to Disclose
 
Pengcheng He
No Relationships to Disclose
 
David Rizzieri
Consulting or Advisory Role - Gilead Sciences; incyte; Kite, a Gilead company; Millennium (I); novartis; onyx (I); pfizer; pharmacyclics; Sanofi; Seagen; Teva
Speakers' Bureau - Celgene; Celgene (I); Gilead Sciences; incyte; Millennium (I); Seagen
 
Yuqin Song
No Relationships to Disclose
 
Bijan Nejadnik
Employment - Eureka Therapeutics
Leadership - Eureka Therapeutics
Stock and Other Ownership Interests - Eureka Therapeutics
 
Jun Zhu
No Relationships to Disclose
 
Cheng Liu
Employment - Eureka Therapeutics
Leadership - Eureka Therapeutics
Stock and Other Ownership Interests - Eureka Therapeutics
Travel, Accommodations, Expenses - Eureka Therapeutics